Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance

This publication has 41 references indexed in Scilit:

• Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
  The Lancet, 2005
• Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations
  JNCI Journal of the National Cancer Institute, 2005
• Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
  New England Journal of Medicine, 2005
• Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
  New England Journal of Medicine, 2005
• KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
  PLoS Medicine, 2005
• EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
  Proceedings of the National Academy of Sciences, 2004
• Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2004
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
  Science, 2004
• Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
  New England Journal of Medicine, 2004
• Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non–Small-Cell Lung Cancer
  Journal of Clinical Oncology, 2004